Anti-Mullerian Hormone (AMH) as Marker of Ovarian Reserve

Summary

This is a multicentre, prospective study willing to evaluate AMH levels changes in response to chemotherapy plus GnRHa. In the present study we propose to determine AMH levels in breast cancer patients, aged \<40yrs receiving adjuvant chemotherapy and ovarian suppression by means of GnRHa with the aim to assess the role of AMH as surrogate marker of the preservation of ovarian reserve exerted by GnRHa.

Timeline

Start

2013-05

Primary completion

2016-05

Completion

2016-12

Drugs

Indications